


Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT	ADJUVANT	INTRA-OPERATIVE	MOLECULAR FAILURE
CCTG-CO32 (NEO-RT trial) (opened 4/29/24) Coord: P. Yang PI: Dr. Zell Accrual: 3/5	NRG-GI008/CIRCULATE (ctDNA guided Tx) (opened 9/14/22) Coord: A. Ballard PI: Dr. Zell Accrual: 5/10	UCI 24-103 (Y90 Resin Spheres vs SOC of mCRC liver metastases) Coord: TBD PI: Dr. Abi-Jaoudeh <u>Pending activation</u>	UCI 20-43 (IP + Irinotecan) (opened 5/24/22) Coord: A. Ballard PI: Dr. Dayyani Accrual: 14/17



UCI 25-149

(Metformin use for Pseudomyxoma
Peritonei secondary to appendiceal
mucinous neoplasms)

Coord: C. Jonsson

PI: Dr. Eng

Pending activation

Newly Diagnosed

Advanced/Metastatic

Neoadjuvant

UCI 21-191
(SOC w/ ctDNA testing)

(opened 6/27/25)

Coord: A. Ballard
PI: Dr. Dayyani
Accrual: 12/20

UCI 23-184
(Pafolacianine for Imaging of Peritoneal Carcinomatosis)

Coord: L. Mejia
PI: Dr. Senthil
Accrual: 9/10

ESCC

UCI 24-77
(I-DXd)

(opened 2/5/26)

Coord: C. Jonsson
PI: Dr. Dayyani
Accrual: 0/5

Newly Diagnosed Metastatic

A022102
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: C. Jonsson
PI: Dr. Dayyani
Accrual: 9/14

UCI 21-10
(FOLFOX + nivo + TJ033721 (anti-CLDN18.2 + anti-4-1BB)

Coord: M. Nguyen; C. Jonsson
PI: Dr. Dayyani
Accrual: 36/50

UCI 26-78
(Sonesitatur Vedotin + Capecitabine +/- Rilvegostomig)

Coord: TBD

PI: Dr. Dayyani
Pending activation

EA2234
(IP/IV Paclitaxel + 5-FU/LV vs. SOC)

(opened 8/28/25)

Coord: L. Mejia
PI: Dr. Senthil
Accrual: 12/65

UCI 25-203
(Pumitamid + Chemo vs. Nivo + Chemo)

(opened 5/27/26)

Coord: N. Ferrand
PI: Dr. Dayyani
Accrual: 0/5

Recurrent

UCI 16-94
(Tirapazamine + Nivolumab)

Coord: S. Duong
PI: Dr. Abi-Jaoudeh
Accrual: 37/48

UCI 24-49
(Zongertinib + Trastuzumab + Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

UCI 23-173
(Tremelimumab and Durvalumab in ARID1 mutated)
(opened 5/29/26)

PI: Dr. Dayyani
Accrual: 0/34

UCI 26-60
(ASP546C)

Coord: TBD

PI: Dr. Dayyani
Pending activation

HER-2	KRAS	EGFR	CLDN18.2
<u>ETCTN-10495</u> (DS8201a + Neratinib) (opened 3/5/25) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 2/7	<u>UCI 25-163</u> (BBO-11818) Coord: K. Buttigieg PI: Dr. Arter <u>Pending activation</u>		<u>UCI 21-10</u> (FOLFOX + nivo + TJ033721 (anti-CLDN 18.2 + anti-4-1BB) Coord: M. Nguyen/C. Jonsson PI: Dr. Dayyani Accrual: 36/50
<u>UCI 24-49</u> (Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecan) (opened 10/22/24) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 3/10			<u>UCI 26-78</u> (Sonesitug Vedotin + Capecitabine +/- Rilvegostomig) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>
			<u>UCI 26-60</u> (ASP546C) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>

UCI 23-85 (BA3182 + (EPCAM/CD3 AB) (opened 9/19/24) Coord: P. Yang PI: Dr. Valerin Accrual: 8/18	UCI 22-26 (Androgen and glucocorticoid receptor antagonist) Coord: B. Nguyen PI: Dr. Dayyani Accrual: 11/12	ETCTN-10579 (ZEN-3694) + capecitabine) (opened 10/27/23) Coord: P. Yang PI: Dr. FC Lee Accrual: 2/4	UCI 21-241 (ALK inhibitor NLV-655) (opened 10/4/22) Coord: A. Ballard PI: Dr. Nagasaka Accrual: 20/25
UCI 25-16 (ODM-212) (opened 8/29/2025) Coord: P. Yang PI: Dr. Dayyani Accrual: 8/10	ETCTN-10572 (Temozolomide + M1774) (opened 12/11/2025) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 2/10	UCI 24-113 (BMS-986482 +/- immunotherapy) (opened 9/29/2025) Coord: L. Mejia PI: Dr. Chow Accrual: 5/10	UCI 25-75 (CRN09682- on SST2 tumors) (opened 2/18/2026) Coord: S. Duong PI: Dr. Dayyani Accrual: 0/15
UCI 24-138 (Tarlatabab in DLL3 Expressing Tumors + Neuroendocrine Neoplasms) (opened 10/31/2025) Coord: N. Ferrand PI: Dr. Park Accrual: 2/5	UCI 24-142 (IV/iTu VET3-TGI +/- atezolizumab) (opened 3/7/2025) Coord: N. Ferrand PI: Dr. Uchio Accrual: 2/4	UCI 25-181 (TAK505) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>	UCI 25-190 (STOPGAP-B) (IP Paclitaxel + SOC in GI Malignancies with Peritoneal Carcinomatosis) Coord: TBD PI: Dr. Senthil <u>Pending activation</u>



UCI 03-03

(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

UCI 22-55

(Early Detection and Diagnosis
of DNA Repair Deficient
Hereditary Cancers)

(opened 3/13/2025)

PI: Dr. Pannunzio/Dr. Valerin
Accrual: 16/50

UCI 24-05

(Riluzole for Cancer- related
Cognitive Impairment)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 26/59

UCI 25-48

(Riluzole For Preventing
Cognitive Dysfunction in
Pts Receiving Chemo)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 6/20